Avid Bioservices Inc (CDMO)

[biopharm]

Is this the first time Peregrine publically mentioned with Epiontis?....seems like all those samples could play into having all in support of one of the BIOMARKERS since all samples don't have to be directly from a Peregrine trial

______________________

Epiontis' experience

72 clinical trials

57,672 samples

September 19, 2017

http://www.epiontis.com/about-epiontis/team/

________________


Interesting interview and now they work with Peregrine ...(even the mention of MDSCs).....hmmmm

Thomas Kleen:
In regards to my work with the Society for Immunotherapy of Cancers, Immune Biomarker Taskforce I should mention that this is the second time that the taskforce members have met. We already had one biomarkers taskforce from 2009 to 2012, but the Biomarkers Taskforce reconvened in 2014 until the present date due to the advances that have been made in cancer immunotherapy, including positive results from clinical trials that I have mentioned earlier and in testing new agents and combinations as well as there is a focus on emerging new technologies for measuring these aspects of immunity where Epiontis’ technology is one of them.

Current focus of the taskforce is to review the state of the identify count hurdles for the success and make accommodations to the field again. Topics being addressed actively right now from the different working groups are validation of candidate biomarkers, so identifying the biomarkers to classify different patients and how they respond.
...
...
http://www.moleculardxeurope.com/mdxe_content.aspx?id=174507